2023 World Conference on Lung Cancer (Posters)-EP06.03. HRR Gene Mutations- A New Biomarker for Precision Genomics Based Testing in Metastatic Lung Cancer

EP06.03. HRR Gene Mutations- A New Biomarker for Precision Genomics Based Testing in Metastatic Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

A study conducted by researchers from the All India Institute of Medical Sciences and Memorial Health System analyzed a total of 228 cancer patients with metastatic lung cancer to determine the prevalence of Homologous Recombination Repair (HRR) gene mutations. Out of the 30 patients in the study, 26.66% had at least one HRR gene mutation, while 73.33% were HRR gene wild-type. The study found no statistically significant difference in tumor mutation burden (TMB) or PD-L1 status between the HRR gene mutated and HRR gene wild-type groups. The study also identified the HRR genes that were mutated in the patients, including ATM, ARID1A, BARD1, BRCA1, BRCA2, BRIP1, CKD12, CHEK1, CHEK2, FANCA, FANCE, FANCG, PALB2, PPP2R1A, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L.<br /><br />The study highlights the importance of precision genomics-based targeted therapy in metastatic lung cancer and the potential for further clinical trials combining PARP inhibitors with immunotherapy in the future. It also emphasizes the need for biomarker testing, such as HRR gene mutations, to guide treatment decisions.<br /><br />The study did not receive any funding, and the authors have declared no conflicts of interest. The authors also provide their contact information for further inquiries.<br /><br />The study categorized the patients' first-line systemic therapy into chemotherapy, immunotherapy, or targeted therapy, with chemotherapy being the most common choice. The study aims to develop a new biomarker-based next generation sequencing (NGS) testing for HRR gene mutations and investigate its relationship with immunotherapy biomarkers.<br /><br />Overall, this study provides valuable insights into the prevalence of HRR gene mutations in metastatic lung cancer and highlights the potential for precision genomics-based targeted therapy in this population.

Asset Subtitle

Madhu Nagaraj

Meta Tag

Speaker Madhu Nagaraj

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

metastatic lung cancer

HRR gene mutations

tumor mutation burden

PD-L1 status

precision genomics-based targeted therapy

PARP inhibitors

immunotherapy

biomarker testing

chemotherapy

NGS testing